Denis A. Smirnov

A phase 1 study of VAC85135, a neoantigen vaccine regimen targeting calreticulin and JAK2 mutations, in combination with ipilimumab in patients with myeloproliferative neoplasms

Salman Otoukesh, Bethan Psaila, Andrew Tucker Kuykendall, Aaron Thomas Gerds et autres

Abstract Disease-specific somatic mutations (mut) in calreticulin ( CALR ) and JAK2 ( JAK2V617F ) are drivers of myeloproliferative neoplasms (MPNs), causing generation of immunogenic peptide epitopes hypothesized to be vaccine-targetable neoantigens. VAC85135, a heterologous prime-boost vaccine regimen comprising adenoviral and vaccinia …

us, gb (code pays fourni par la source)

Benchmarking single-cell foundation models for real-world RNA-seq data integration

Siyu Han, Tamas Ryszard Sztanka-Toth, Enes Senel, Ahmed Elnaggar et autres

Abstract Single-cell foundation models enable reusable representations and streamlined analysis workflows, yet rigorous evaluation of their performance and robustness in real-world pharmaceutical settings remain underexplored. Here, we benchmarked leading single-cell foundation models (scGPT; scGPT_CP, a continually pretrained checkpoint of scGPT; scFoundation; scMulan; …

us (code pays fourni par la source)

Abstract 796: Digital spatial profiling reveals immune heterogeneity across tumor and stromal compartments in hepatocellular carcinoma.

M. Qing, Qibiao Wu, Xuesong Lyu, T. Timothy Chen et autres

Abstract Introduction: Hepatocellular Carcinoma (HCC) is one of the most devastating malignancies around the world, especially in East Asia. Despite significant advances in immune checkpoint inhibitors in the past decade, many patients show poor response, highlighting the need to better understand tumor …

us, tw (code pays fourni par la source)

Benchmarking Next-Generation Sequencing Platforms: A Comprehensive Comparison Of Single-Cell RNA-Seq from Ultima UG 100 vs. Illumina NovaSeq X Plus

Ruoyun Xiong, Jaymala Patel, Tamas Ryszard Sztanka-Toth, Enes Senel et autres

Abstract Single-cell RNA sequencing (scRNA-seq) has become an essential technology for dissecting cellular heterogeneity in complex biological systems, with Illumina platforms serving as the dominant NGS provider 1–3 . The recent emergence of the Ultima Genomics UG 100 platform offers a high-throughput …

us (code pays fourni par la source)

Earlier use of ciltacabtagene autoleucel (cilta-cel) is associated with better immune fitness and stronger immune effects as shown by correlative analysis of peripheral blood and the bone marrow tumor microenvironment (TME) from the CARTITUDE-4 study

Samir Sunil Parekh, Katherine T Li, Niels W.C.J. van de Donk, Yi Lin et autres

Abstract Introduction: Cilta-cel is approved in the US and the EU for the treatment of patients (pts) with lenalidomide-refractory multiple myeloma (MM) after ≥1 prior line of therapy (pLOT), including a proteasome inhibitor and an immunomodulatory agent based on the CARTITUDE-1 (CART-1, …

us, au (code pays fourni par la source)

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma

Simon James Harrison, Cyrille Touzeau, Nicolas Kint, Katherine Li et autres

-mutated T cells, followed by acquisition of further oncogenic genomic variants. Other potential contributors include germline genomic variation, viral infections, and previous treatment for myeloma. In the absence of direct evidence, the contribution of insertional mutagenesis to the development of T-cell lymphoma …

au, fr, be, us, de, gb (code pays fourni par la source)

1973P Urine-based molecular testing identifies FGFR alteration-positive patients for treatment with TAR-210

Félix Guerrero‐Ramos, Ja Hyeon Ku, A. Vilaseca, C.X. Raventos et autres

es, kr, us (code pays fourni par la source)

Urine-based testing for patient selection and genomic characterization of patients with FGFR alteration-positive non–muscle-invasive bladder cancer (NMIBC) treated with TAR-210.

Roger Li, Ja Hyeon Ku, Antoni Vilaseca, Félix Guerrero‐Ramos et autres

676 Background: TAR-210 is an intravesical drug delivery system that is designed to provide local, continuous release of erdafitinib. Its safety and efficacy are being evaluated in a first-in-human clinical study (NCT05316155) of patients with bladder cancer whose tumors harbor select FGFR …

us, kr, es (code pays fourni par la source)

Biomarker Correlates of Response to Ciltacabtagene Autoleucel in Patients with Relapsed or Refractory Multiple Myeloma from CARTITUDE-1, a Phase 1b/2 Open-Label Study, at the ~3 Year Follow-up

Rocio Montes De Oca, Junchen Gu, Hao Zhao, Kathy Zelinsky et autres

Ciltacabtagene autoleucel (cilta-cel) consists of autologous T cells genetically modified to express a two-binding domain chimeric antigen receptor (CAR). The target antigen of the CAR is B-cell maturation antigen (BCMA), which is highly expressed on malignant plasma cells (PC) from multiple myeloma …

us, be (code pays fourni par la source)

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Simon James Harrison, Tamia Nguyen, Marzia Rahman, Jeremy Er et autres

Introduction:Rareevents of T-cell lymphoma (TCL) derived from CAR-T cells (2 cases) have been reported in patients receiving nonviral piggyBac transposon-based CAR-T therapy (Micklethwaite et al, Blood, 2021). Ciltacabtagene autoleucel (cilta-cel) is an anti-BCMA CAR-T therapy produced via conventional lentiviral transduction. In the …

au, us, be (code pays fourni par la source)

1213P HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer

X. Ye, Umesh Singh, Yang Guo, Jian Wang et autres

cn, us (code pays fourni par la source)

Supplementary Figure S1 from Global Gene Expression Profiling of Circulating Tumor Cells

Denis A. Smirnov, Daniel R. Zweitzig, Bradley W. Foulk, Michael Craig Miller et autres

Supplementary Figure S1 from Global Gene Expression Profiling of Circulating Tumor Cells